Finanzen von Day One Biopharmaceuticals Inc (DAWN)DAWNDay One Biopharmaceuticals Inc

Evaluating the bottom line, Day One Biopharmaceuticals Inc maintains a gross margin of 88.68%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -51.12%, while the net margin is -39.61%. These profitability ratios, combined with a Return on Equity (ROE) of -22.74%, provide a clear picture of how effectively DAWN converts its operational activities into shareholder value.

In the context of the broader market, DAWN competes directly with industry leaders such as DFTX and SRPT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, DAWN's gross margin of 88.68% stands against DFTX's N/A and SRPT's 62.59%. Such benchmarking helps identify whether Day One Biopharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

In Q4 2025, revenue increased by 83.92% YoY to $53.7M, but net income dropped by -67.62% YoY to -$21.28M. EPS also declined by -67.19% YoY to -$0.21, and gross margin slightly decreased to 88.68%.